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Abstract
Background: Because of a high cardiovascular disease (CVD) risk in people with Familial Hypercholesterolemia
(FH), early prevention of cardiovascular disease is important for health gain and cost reduction. This project focuses
on the development and evaluation of an innovative intervention aiming to reduce CVD risk by promoting a
healthy lifestyle among people with FH.
Methods: This project is designed as a randomised controlled trial in which individuals with FH will be assigned
randomly to a control or intervention group. In the intervention group (n = 200), participants will receive a
personalized intervention which is a combination of web-based tailored lifestyle advice and personal counselling
by a lifestyle coach. The control group (n = 200) will receive care as usual. Primary outcomes are biological
indicators of CVD risk: systolic blood pressure, glucose, BMI, waist circumference and lipids (triglycerides, total, LDL
and HDL cholesterol). Secondary outcomes are: healthy lifestyle behaviour (with regard to smoking, physical
activity, dietary pattern and compliance to statin therapy) and psychological correlates and determinants of healthy
lifestyle behaviour (knowledge, attitude, risk perception, social influence, self-efficacy, cues to action, intention and
autonomy). Measurement will take place at baseline, and at 3 and 12 months after randomisation. Additionally, a
throughout process-evaluation will be conducted to assess and monitor intervention implementation during the
trial.
Discussion: Results of the PRO-FIT project will provide information about the effects and implementation of a
healthy lifestyle intervention for individuals with FH. Our experiences with this intervention will be indicative about
the suitability, feasibility and benefits of this approach for future interventions in other high-risk groups, such as
Familial Combined Hypercholesterolemia (FCH) and diabetes.
Trial registration number: NTR1899
Background
Familial hypercholesterolemia (FH) is an autosomal
dominant disorder of the lipoprotein metabolism. Due
to a defect of the low density lipoprotein (LDL) receptor
gene, plasma concentrations of LDL cholesterol (LDL-C)
are elevated[1]. In the Netherlands, approximately one
in 300 people is affected with the heterozygous type of
FH[2]. In 2003, the Ministry of Health, Welfare, and
Sports introduced a national cascade screening program
to detect people with FH. The screening program is run
by the Foundation for Tracing Hereditary Hypercholes-
terolemia (StOEH) and through this program, some tens
of thousands of people in the Netherlands have already
been and are made aware that they have FH[3].
Elevated serum LDL-C and therefore also FH is asso-
ciated with an elevated risk of premature cardiovascular
disease (CVD)[4], which is the disease with the highest
burden in disability adjusted life years (DALYs) in the
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treated, the cumulative risk of developing coronary
artery disease (CAD) by the age of 60 years is over 60%
for men, and over 30% for women[6]. This increased
risk does not appear to make people with FH more wor-
risome[7]. They seem to underestimate their CVD risk
[8] and perceive it similar to those in whom no muta-
tion was found[7].
A substantial number of LDL-C mutation carriers are
identified through the national screening program. How-
ever, a large variety in phenotypic expressions among
FH carriers has been found[9]. Environmental factors,
lifestyle factors in particular, appear to play an impor-
tant role in modulating the course of this disorder
[10,11]. Until now, research has mainly been focussed
on the effectiveness of pharmaceutical therapy, whereas
achieving improvement by lifestyle change has hardly
been investigated. Large primary and secondary preven-
tion trials with statins have clearly demonstrated the
benefit of reducing LDL-C in subjects with high LDL-C
[12,13]. Statin therapy is the cornerstone of dyslipidemic
management for people with FH, but significant CVD
risk persists despite effective LDL-C lowering statin
treatment[14]. Two main strategies are of importance to
further reduce CVD risk among FH patients: 1)
Improvement of adherence to statin therapy, and 2)
Improvement of CVD-risk-related lifestyle. Large pro-
portions of individuals with FH receive lipid-lowering
statin therapy and still do not achieve LDL-C target
levels as stated by the guidelines of the National Choles-
terol Education Program (NCEP)[15]. Even though com-
pliance to medication seems high, still 12% of the
people with FH never started, and 6.4% discontinued
their medication after identification of FH[16]. Addi-
tional activities to promote treatment (adherence) have
the potential to be effective in reducing CVD risk in
these groups.
A healthy lifestyle is an aspect of the treatment of FH
with many benefits beyond LDL-C-lowering drugs[17].
Results of primary prevention trials in high-risk persons
and secondary prevention trials in CVD patients both
show that substantial reductions in the CVD risk can be
obtained through lifestyle changes[18]. For example, the
INTERHEART study showed that eating fruit and vege-
tables daily, being physically active regularly and avoid-
ing smoking were effective in reducing the risk of a
myocardial infarction by 80%[19].
Altogether, these findings indicate that more compre-
hensive treatment of dyslipidemia is needed among FH
patients to establish treatment goals. Raising awareness
of the actual CVD risk, lifestyle improvement and
improving compliance to statin therapy are promising
strategies in reducing CVD risk among people with FH.
There is a lack of evidence-based interventions that
incorporate this comprehensive approach in the Nether-
l a n d sa sw e l la se l s e w h e r e .O u re x p e r i e n c e sw i t ht h i s
intervention will be indicative about the suitability, feasi-
bility and benefits of this approach for future interven-
tions in other high-risk groups, such as Familial
Combined Hypercholesterolemia (FCH) and diabetes.
The PRO-FIT project aims to develop such a compre-
hensive tailored lifestyle intervention and to evaluate
this intervention in a randomized controlled trial, sup-
ported by a process and cost evaluation. In this article,
we aim to outline the intervention and research design
of the PRO-FIT project. PRO-FIT stands for promoting
a healthy lifestyle in people with FH through an indivi-
dually tailored lifestyle intervention.
Methods/Design
Development of the intervention
The PRO-FIT intervention was developed in a stepwise
fashion, informed by a comprehensive theoretical frame-
work and supported by an external advisory group. The
advisory group brought together experts on behavioural
change, computer tailored health education, and on FH
and cardiovascular diseases. Their feedback and input
was used to develop the intervention, and will be used
during the intervention trial.
Theoretical framework
The intervention of the PRO-FIT project was developed
according to the integrated model for exploring motiva-
tional and behavioural change, the I-Change model (2.0)
[20]. The core of the I-Change model is the Attitude-
Social Influence-Self-efficacy (ASE) model which is com-
parable to the Theory of Planned Behaviour [21], but
incorporates modelling and social support as social
influences besides subjective norms. The I-Change
model combines the ASE model with insight from stages
of change models [24,25] and action planning models
[26,27] to provide a comprehensive framework to study
and facilitate behaviour change processes. It assumes
that the behavioural change process can be distin-
guished in three phases: 1) Awareness, 2) Motivation
and 3) Action. For each phase, specific change determi-
nants have been proposed.
In the ‘pre-motivational’ awareness phase, people need
to become aware of their risk behaviour. Important fac-
tors to proceed through this phase according to I-
Change are knowledge, risk perceptions, and cues that
prompt people to become aware. In the motivational
phase, people need to become motivated to change their
behaviour. Important factors in this phase according to
t h eI - C h a n g em o d e la r ea t t i t udes, social support and
self-efficacy expectations. Proceeding through the moti-
vational phase results in positive intention to change
one’s behaviour. In the action phase people need to
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phase several preparatory actions to facilitate behaviour
change need to be planned and executed. People should
convert their more global goal intentions into specific
implementation intentions or action plans, with relevant
strategies that will enable them to attain their goal.
For a detailed overview of the I-Change model, see
figure 1.
Strategies
During the development of the PRO-FIT intervention,
we aimed to focus on the earlier-mentioned factors of
behavioural change identified in the I-Change model. A
more detailed description of these factors, the strategies
that will be employed, as well as the intervention com-
ponents are outlined in table 1.
Risk communication
To raise awareness, participants will be presented with
CVD risk information. Due to the predispositional char-
acter of the risk and its high dependency on medication
use and current lifestyle behaviour, it is not possible to
present participants with a valid, accurate personal
numeral risk. Rather, participants will be presented with:
1)feedback on CVD risk behaviours to educate them
about the contribution of these CVD risk factors to
their overall CVD risk, 2)information on the changeabil-
ity of these factors, and 3)cues about how these risk
behaviours may be changed. The risk factors, their chan-
geability and the cues to action will be presented to the
participants on a personal webpage.
Computer tailoring
Earlier research has shown that computer-tailored edu-
cation is an innovative and promising method to moti-
vate people to change their physical activity and dietary
behaviours, and it has shown better effects than generic
health education[23]. The fact that computer-tailored
health education provides people with personalized feed-
back and advice is probably the main determinant of its
effectiveness[24].
In this project, online tailored advice is focused on
saturated fat intake, fruit and vegetables intake, physical
activity, smoking behaviour and compliance to statin
therapy. Online advice on saturated fat intake, physical
activity and smoking behaviour is based on existing tai-
lored information modules of the ‘H e a l t h yL i f eC h e c k ’
(in Dutch: ‘Gezondlevencheck’)o ft h eN e t h e r l a n d s
Heart Foundation. This web-based computer-tailored
lifestyle intervention was evaluated by Oenema et al [25]
Figure 1 I-Change model 2.0. An integrated model for exploring motivational and behavioural change, used as theoretical framework during
the development of the PRO-FIT intervention.
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activity. Computer-tailoring is focused on personal per-
formance level (current lifestyle behaviour), awareness
of their own performance, as well as personal motiva-
tion to change, outcome expectations, attitude and self-
efficacy. Since CVD risk reduction can be achieved by
daily fruit and vegetable intake as well [19], online tai-
lored advice modules on fruit and vegetables are added
to the online tailored advice, mainly based on existing
modules of the Live Healthy Coach (in Dutch: Leefge-
zondcoach) of the Dutch Diabetes Federation, developed
at the Erasmus University Medical Center in Rotterdam,
the Netherlands. Personalized feedback on compliance
to statin therapy will be given through an existing tai-
lored information module, tailoring on knowledge and
personal beliefs about (the effect of) statin therapy,
potential side effects of the prescribed drug and current
compliance. This module was developed at the Rijksuni-
versiteit Groningen, the Netherlands. Additionally, a
short-term plan and potential barriers to achieve this
plan can be formulated in the online system.
These tailored advice modules are integrated into one
online PRO-FIT*advice environment, a website that par-
ticipants can visit using their personal account.
For the PRO-FIT computer-tailored intervention we
have taken the main limitations into account identified
in the main systematic review of effectiveness of compu-
ter-tailoring in the behavioural nutrition and physical
activity field[23]. More specific, PRO-FIT combines
web-based education with interpersonal counselling, and
thereby combines repeated exposure to the intervention
with individualization of messages and a social
component.
Motivational interviewing
Motivational interviewing (MI) was chosen as a techni-
que to counsel the participants towards the desired
behavioural change. MI was developed by Miller and
Rollnick [26] and is a useful intervention strategy in
behaviour change interventions[27]. MI is directive, but
client-centred and its main goal is to facilitate the client
in identifying and mobilizing his or her intrinsic values
and goals related to the targeted behavioural changes.
Meta-analyses indicate that MI can be effective in facili-
tating health behavioural changes across a range of
domains[28,29].
The five main principles of MI are: 1)showing empa-
thy, 2)avoiding discussion, 3)rolling with resistance, 4)
supporting self-efficacy, and 5)raising awareness of a dis-
sonance between actual behaviour and behavioural
goals. The main interviewing strategies of MI are: asking
open-ended questions, showing empathy, reflecting on
the client, confirming and summarizing[26]. In this pro-
ject, brief MI will be performed by a personal coach, a
health professional trained in MI. MI will be done once
face-to-face at the participants’ home and five times by
telephone. The main principles of MI will be used to
develop interview protocols. For telephone counselling,
an adjusted version of the telephone interview protocol
of the Healthy Body Healthy Spirit trial will be used
[30,31].
The PRO-FIT intervention
The intervention consists of a personalized health coun-
selling intervention. This is a combination of tailored
web-based advice (PRO-FIT*advice) and face-to-face
counselling complemented with telephone booster ses-
sions (PRO-FIT*coach).
The goal of the intervention is to: 1) improve aware-
ness of the cardiovascular disease risk through an
increase of specific knowledge, cues to action and
change in risk perception, 2) improve motivation with
respect to healthy behaviour through an increase of spe-
cific knowledge and a change in attitude, self-efficacy
Table 1 Strategies to influence factors of behavioural change
Factors of behavioural change Strategy
Awareness factors knowledge, risk perception and cues to
action
Educating participants on their current CVD risk factors, with regard to their size and
changeability (risk communication). Thereafter, translating this to behavioural
change in their personal situation.
Raising awareness by providing personal and normative behavioural feedback
following motivational interviewing techniques.
Predisposing factors genetic predisposition, current lifestyle,
personal characteristics and information factors.
Tailoring the communication of CVD risk factors and lifestyle counseling to the
genetically predisposed risk of the participants and their personal characteristics (age,
gender, members of the household) and their current lifestyle behaviour.
A multi-channel approach is chosen, thereby offering the intervention by internet,
face-to-face and by telephone.
Motivational factors attitude, social influence and self-efficacy Giving personal feedback to participant’s self-reported attitude and self-efficacy and
by involving the social environment of the participant in making action plans.
Ability factors, Stimulating participants to make action plans and discussing how to overcome
possible barriers in behavioural change, thereby following motivational interviewing
techniques.
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lifestyle, with regard to physical activity, saturated fat
intake, fruit and vegetables intake, smoking and compli-
ance to statin therapy, and 4) lower the level of LDL-C
and other biological CVD risk indicators and thereby a
reduction of the CVD risk.
Risk communication
Participants of the intervention group will receive a web
link that directs them to the project website, where they
can go through a number of web pages providing them
with information about their CVD risk profile. After
going through these web pages, they can log on to the
tailored lifestyle advice (PRO-FIT*advice) with their per-
sonal username and password that are given in the
email.
Computer tailoring
PRO-FIT*advice contains six advice modules on physical
activity, fruit intake, vegetables intake, saturated fat
intake, smoking and compliance to statin therapy. Parti-
cipants can choose what modules to go through and in
w h a to r d e r ,b u tt h e yw i l lb ea d v i s e da n de n c o u r a g e dt o
complete all relevant modules (e.g. the module ‘smoking’
only if the participant is a smoker). For each module,
participants first complete an online questionnaire that
enables assessment of current behaviour and the rele-
vant psychosocial correlates suggested by the I-Change
model. After completion, the PRO-FIT*advice software
will analyse the answers and create personalized feed-
back and behaviour change advice, provided on the
computer screen. More specifically, feedback on current
behaviour in accordance with national recommendations
will be provided and, if the behaviour is not according
to recommendations, suggestions will be given on how
to make relevant behaviour changes. The participants
will be encouraged to make a concrete action plan, i.e.
to specify when, where and how they will make the
changes as well as what preparatory actions are
necessary.
Motivational interviewing
Two weeks after sending their personal PRO-FIT*advice
username and password, participants will be visited at
home by their lifestyle coach. The participant and the
coach will further establish the level of the participant’s
knowledge about FH and cardiovascular risk factors,
and risk perception in a personal counselling session
assisted by the information from the risk communica-
tion web pages. Furthermore, the coach will have access
to the participant’s personal PRO-FIT*advice account
and the advice will be discussed, ambivalence and bar-
riers related to the recommended behaviour changes
will be explored based on MI.
D u r i n gt h e1 2m o n t h so ff o l l o w - u po n et of i v ec o u n -
sellor-initiated booster telephone sessions will be per-
formed. The goal of these calls is twofold: to encourage
the participant’s current behavioural changes and to
provide further brief motivational interviewing to encou-
rage the planned behavioural changes. The number of
telephone sessions will be based on the participant’s
action plans and their need for additional counselling.
The calls will be scheduled with the participant and will
be documented in the form of a personal calendar that
is send to the participant with a small booklet in which
all topics to be addressed during the counselling session
will be listed.
Face-to-face counselling and telephone booster ses-
sions will be performed by two trained lifestyle coaches.
They received a special 3-day training programme on
motivational interviewing techniques. For training pur-
pose, during a pilot study, 20 pilot counselling sessions
were scored by the coaches according to the Motiva-
tional Interviewing Skills Code (MISC)[32] and the
Motivational Interviewing Treatment Integrity Code
(MITI)[33]. According to these scores, and the experi-
ences of the participants and the trainees, the quality of
counselling was discussed and potential points of
improvement were brought up. Each counselling session
will be audio taped and both content and general char-
acteristics will be documented into a database registra-
tion system. Both face-to-face and telephone counselling
will be examined by two trained coders for fidelity to
MI, using Motivational Interviewing Treatment Integrity
(MITI 3.0) code[34]. To promote continued participa-
tion in the PRO-FIT trial, participants in both study
groups will receive three incentives during the course of
the trial.
Pilot study
A pilot study to test the feasibility of the intervention
and measurement content and procedures of the PRO-
FIT trial was conducted in November 2008. Twenty
participants from the target population were recruited
for this pilot following the same recruitment strategies
as are intended for the trial. All 20 participants com-
pleted the measurement and intervention in a one
month time frame. Participants were interviewed and
surveyed about their appreciation and logistics of and
experiences with the measurement and intervention.
Based on the pilot, minor adjustments were made in
the content and procedure of both the measurement
and intervention.
Evaluation of the intervention
This PROFIT trial is designed as an RCT. Participants
will be randomly assigned to either intervention or con-
trol group. In the intervention group, the participants
will receive the comprehensive intervention as described
above. Participants in the control group will receive
usual care, which means that they will receive no
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collection continues until the summer of 2010.
The project design, procedures and informed consent
form were approved by the Medical Ethics Committee
of the VU University Medical Center (under registration
number 2008/149), and all participants provide written
informed consent.
Study population
Participants are individuals who were diagnosed with FH
by StOEH from January 1
st 2007 to April 15
th 2009. The
invitation included an information brochure, a reply
card, an informed consent letter and a reply envelope.
Responders to the invitation are included in the project
if they: 1) are aged 18-70 years, 2) are sufficiently fluent
in Dutch, 3) have given informed consent, 4) have a
LDL-C level that is >75
th percentile (corrected for age
and gender), 5) live in a 150 km radius of Amsterdam,
and 5) have access to the internet.
Sample size
Information is lacking on the Standard Deviation (SD)
of the mean intra-individual change in LDL-C, the main
CVD risk indicator, over one year period of follow-up in
a population that has recently been notified of their
positive FH status. Being conservative, we expect the
change to be large (35%). With an alpha of 0.05, the
mentioned numbers (200 participants in intervention
and 200 in control group) and an expected drop-out of
20%, the power is 90% to statistically detect an interven-
tion effect of 9%. A 10% reduction of LDL-C is asso-
ciated with a 13% reduced risk of major coronary events
[35].
Randomisation
A stratified computerized randomisation procedure will
be carried out using Microsoft
© Office Access 2003 soft-
ware. We will stratify participants according to choles-
terol lowering medication use (yes/no), assuming that
medication use implicates treatment by a general practi-
tioner and/or medical specialist, who could have already
given advice on lifestyle behaviour. In addition, we
expect that a decrease in LDL-C because of the inter-
vention is smaller if a participant already uses medica-
tion. After stratification, the randomisation procedure
will be carried out.
If participants are members of the same household,
cluster randomisation will be performed by clustering
these participants and allocating them randomly to
either the control or the intervention group. This will
be done to prevent contamination of the intervention
effect due to reciprocal communication about the inter-
vention or control condition among participants. Strati-
fication and randomization will be performed by an
independent researcher, who is not involved in the
intervention.
Participant flow
After the participant completed the reply card and
signed the informed consent letter, baseline measure-
ments will be performed and the baseline questionnaire
will be sent out. Thereafter, 400 participants will be ran-
domly assigned to either the intervention (n = 200) or
control group (n = 200). Participants are followed for 12
months. For a detailed flow chart, see figure 2.
Measurements
Biological CVD risk indicators
LDL-C, HDL-C and total cholesterol, triglycerides and
glucose will be measured with fasting finger stick sam-
ples analyzed on a Cholestech LDX desktop analyzer
(Cholestech, Hayward, USA). This portable analyzer is
capable of providing a lipid profile (LDL-C-, HDL-C
and TC, TC/HDL ratio and triglycerides) and glucose in
approximately 5 minutes, using a lipid profile and glu-
cose test cassette. The reproducibility and precision of
lipids measurement by the LDX analyzer are within the
guidelines of the NCEP[36,37]. The Cholestech LDX
analyzer has been validated for point-of-care lipid mea-
surements in clinical practice[38]. Blood pressure (in
mmHg) is measured twice with a fully automated blood
pressure monitor. The right arm is placed on a table
and a cuff is placed on the right upper arm. Participants
with a blood pressure of 140/90 mmHg or higher will
be advised to visit their general practitioner. The mean
value of the two measurements will be computed.
BMI and waist circumference
Height (in cm) will be measured on bare feet with a
portable device with a wide measuring slide and a heel
plate. Calibrated scales will be used to determine body
weight (in kg) while participants wear light clothing only
(e.g. underwear). Both weight and height will be mea-
sured twice, and the mean value of the two measure-
ments will be computed and used to calculate BMI.
Waist circumference (in cm) will be measured twice
with a measurement tape to the nearest 0.1 cm, at the
midpoint between the lower border of the ribs and the
upper border of the pelvis. The mean value of the two
measurements will be computed.
A l lm e a s u r e m e n t sw i l lb ep e r f o r m e db yat r a i n e d
research assistant at the beginning of participation (M1
in figure 2) and after 12 months (M2 in figure 2).
Questionnaires
Lifestyle behaviours
The level of physical activity will be measured by the
Short QUestionnaire to ASsess Health-enhancing physi-
cal activity (SQUASH), which has been found to be
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valid[39]. The focus regarding dietary intake is on satu-
rated fat, fruit and vegetable intake, and will be mea-
sured by the short Dutch questionnaire on total and
saturated fat intake[40,41] and on fruit and vegetable
intake[42]. These questionnaires have been validated as
related to seven day dietary records (47-49). For the
fruit and vegetable questionnaire also biomarker validity
was established[43]. Smoking behaviour will be assessed
by a self-reported measure, asking participants if they
are a current smoker, an ex-smoker, or a never smoker,
how many years they smoke(d) and how many cigarettes
or other tobacco products they smoke(d) a day[44].
Self-reported compliance to statin therapy
The five-item Medication Adherence Report Scale
(MARS-5) will be used to measure self-reported compli-
ance to statin therapy, which was found to have good
reliability and validity[45]. In addition, pharmacy records
will be used to study the persistence of medication use
(period from first prescription to discontinuation) and
refill compliance (percentage of prescribed medication
that was actually obtained at the pharmacy). Permission
to consult pharmacy records will be asked in the
informed consent form.
Intention
Intention to change will be assessed with a self-report
measure, asking participants: Do you plan to change
behaviour X. The behaviour and the change was speci-
fied according to recommendations (e.g. raise the level
of physical activity to >30 minutes a day) on a 5-point
Likert scale ranging from certainly yes to certainly no.
Additionally the participants will be asked how certain
they were about acting upon their intention and How
sure are you of this? (absolutely sure to absolutely not
sure).
Risk perception
Leventhal’s self-regulation model of illness cognition
(SRM) provides a useful framework for considering and
assessing the role of risk perception in response to com-
municating CVD risk to people with FH[46]. According
to this model, a health threat activates a self-regulatory
process where initially a coherent, common-sense
understanding of the problem is developed. The cogni-
tive illness-risk representations that are formed can be
translated to the five core constructs of the SRM: iden-
tity, causal beliefs, timeline, consequences and control
[47]. Questions on risk perception were developed from
the literature and partly based on the brief Illness Per-
ception Questionnaire (IPQ), the revised IPQ (IPQ-R)
[48,49] and questionnaire of Claassen et al[50]. The con-
structs of the IPQ and IPQ-R are mainly based on the
five elements of the SRM.
Participants will be asked if they actually know about
their CVD risk and if they know how to reduce this
risk, on a 5-point Likert scale ranging from I totally dis-
agree to I totally agree. Emotional representation of
CVD risk will be assessed questioning When I think of
my CVD risk, I feel... on a 7-point Likert scale ranging
from not anxious at all to very anxious and not worried
at all to very worried.
The perceived CVD risk will be assessed questioning
the comparative risk (Of 100 men/women of my age, I
think that approximately .... people will develop a CVD
within the next 10 years), the verbal perceived risk (How
likely is your chance of getting a CVD within the next 10
years?) and verbal comparative risk (According to you,
what is your chance of developing a CVD within the
Invitation people with FH-status 
-  Information about the study 
-  Informed consent letter 
-  Baseline electronic questionnaire Q1  
 
Baseline measurement M1 
Intervention group 
N=200 
Control group 
N=200 
PRO-FIT*advice 
 
PRO-FIT*coach: 
face-to-face 
counselling 
No intervention 
 
 
 
 
 
 
Questionnaire 
Q3 
Time in 
weeks 
0 
2 
4/5 
6/7 
8 
4 
Follow-up 
measurement 
M2 
Stratification and (cluster) randomization 
Positive reply (n=400) 
1-5 counsellor-
initiated booster 
calls  
52 
Questionnaire 
Q2 
Incentive 1  
Incentive 2 
Incentive 3 
48 
Figure 2 Participant flow. A detailed participant flow chart of the
PRO-FIT project.
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your age without FH?) both on a 7-point Likert scale
ranging from very unlikely to very likely. Additionally,
we will assess perceived CVD risk from a personal point
of view, questioning For your own feeling, how big is
your chance of developing a CVD within the next 10
years?’ on a 7-point Likert scale ranging from very small
to very big. Finally, participants will be asked to score
whether twenty possible causal beliefs (p.e. Ie x p e c t
chance or bad luck as a potential cause for CVD)f o r
CVD were applicable to their situation. Furthermore,
participants will rank what they thought were the three
most important causes.
Psychosocial factors
Attitude, self-efficacy and social influence will be mea-
s u r e do na5 - p o i n tL i k e r ts c a le ranging from (attitude)
very bad to very good, (self-efficacy) very difficult to very
easy and (social influence of partner, relatives, children,
friends and/or experts) from I totally agree to It o t a l l y
do not agree. Whether (a relative) having FH, (a relative)
having CVD, an elevated CVD risk and/or death of a
relative through CVD were cues to change lifestyle
behaviour, will be measured on a 5-point Likert scale
ranging from I totally agree to It o t a l l yd on o ta g r e e .
The psychosocial factors mentioned above will be mea-
sured with regard to all lifestyle behaviours, as well as to
compliance to statin therapy. In addition, preference for
autonomy will be measured with one item, asking In
general, when it comes to my health, I would rather
have an expert tell me what I should do on a 5-point
Likert scale ranging from I totally agree to It o t a l l yd o
not agree. Response efficacy will be measured on a simi-
lar scale, assessing whether the participant believes sta-
tin treatment and lifestyle improvement are effective in
reducing CVD risk.
Electronic questionnaires will be sent to the partici-
pants at the beginning of participation (Q1 in figure 2)
and after 12 months (Q3). Additionally, risk perception
will be measured after 3 months (Q2 in figure 2), and
preference for autonomy will be measured after 12
months (Q3).
Statistical analysis
Multiple linear and logistic regression analysis techni-
ques will be performed. Potential confounders and effect
modifiers (i.e. gender and age) will be checked. Data will
be analysed according to the intention-to-treat principle.
Process evaluation
A thorough systematic approach is chosen to monitor
and document the implementation of the intervention
d u r i n gt h et r i a l .B yu s i n gt h eR E - A I Mf r a m e w o r k ,t h e
translatability and public health impact of our project
will be repeatedly evaluated by examining our work in
light of the following five dimensions: 1) Reach among
the target population; 2) Efficacy of the intervention; 3)
Adoption by intermediaries; 4) Implementation - consis-
tency of delivery of intervention; 5) Maintenance of
intervention effects in individuals and populations over
time[51]. Consequently, a structured process evaluation
plan is developed according to Saunders[52]. A systema-
tic approach is chosen to asses the implementation of
the intervention, including recommended elements like
fidelity, dose (delivered and received), reach, recruitment
and context. Process evaluation questions are formu-
lated on each element and accompany the questionnaire
at 3 months (Q2) and at follow up (Q3).
Economic evaluation
Economic evaluation consists of an analysis of differ-
ences in intervention development and implementation
between the intervention and control group. The incre-
mental costs of the intervention group compared to the
control group will be divided by the incremental effect
for the percentage improvement in LDL-C. The 95%-CI
for these ratios is calculated using bootstrapping meth-
ods and they will be graphically presented on a cost-
effectiveness plane. Utilities for the cost-utility analysis
will be based on the EuroQol questionnaire[53], accom-
panying the questionnaire at baseline (Q1), at 3 months
(Q2) and at follow-up (Q3).
Discussion
In this article, we aim to outline the design of the PRO-
FIT project, which is a RCT on the (cost-) effectiveness
of a tailored lifestyle intervention to reduce the CVD
risk of individuals with FH. The intervention is theory-
driven and works systematically, aiming at a reduction
of CVD risk through improvement of lifestyle beha-
viours and medication adherence.
Anticipated strengths of the approach include: it starts
with aiming at accurate awareness of CVD risk, then
giving evidence-based tailored feedback on lifestyle and
finally, personally motivating people to move towards a
healthy lifestyle. The social interaction during the face-
to-face coaching session complements the single weak-
ness of the individualized web-based approach, and
thereby making this combination a promising one. For-
mer research has shown that similar lifestyle interven-
tions can effectively improve lifestyle behaviour[18].
Limitations of this project are: the study population is
characterized by diversity and similarity at the same
time. Both aspects can cause contamination of effects.
Diversity is mainly due to the expected inter-participant
differences at baseline, regarding biological CVD risk
indicators, lifestyle behaviour, and use and type of medi-
cation. Similarity is caused by the familial nature of FH,
resulting in a population with a high level of mutual
Broekhuizen et al. BMC Public Health 2010, 10:69
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Page 8 of 10communication. Both stratifying our sample on use of
medication, and randomizing them in household clus-
ters are methods to minimize potential contamination.
However, these limitations should be considered during
data analysis.
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